Techstars Ventures

Each accelerator program has a managing director who sources and selects that program's investments, typically 10–12 companies per cohort. The follow-on fund is managed by a central venture team that evaluates accelerator graduates and external seed opportunities, with investment committee oversight from the firm's partners.

The accelerator invests $20,000 for 6% common stock (as of the standard 2024 terms) in exchange for a three-month mentorship program culminating in a Demo Day. The venture fund, operating separately, makes larger follow-on investments from $500,000 to $2 million into accelerator graduates and occasionally into companies outside the Techstars ecosystem.

Both. The firm invests directly into accelerator companies, makes direct follow-on equity investments through its venture funds, and also commits capital as a limited partner to roughly 50 external venture funds, including firms founded by Techstars alumni.

Accelerator-level investment carries a standard $20,000 check for 6% common equity. Follow-on fund checks typically range from $500,000 to $2 million, with reserve allocated for pro-rata participation in later rounds.

The accelerator pipeline is open-application, generating roughly 500 to 1,000 applications per program per city. The venture team accesses this pipeline, attends Demo Days globally, and also reviews external seed deals, giving them proprietary visibility into thousands of early-stage companies annually.

Techstars companies typically donate 1% of their equity to the Techstars Foundation at the time of accelerator acceptance. The foundation holds a diversified equity portfolio from thousands of portfolio companies, using proceeds for grants in entrepreneurship education and diversity programs. The venture arm and the foundation are governed separately.

The firm is thesis-agnostic across technology verticals, actively investing in enterprise software, fintech, AI/ML, digital health, robotics, and climate tech through its generalist accelerator programs. It tends to avoid capital-intensive hardware, life sciences with long regulatory timelines, and companies requiring significant upfront physical infrastructure before product-market fit is demonstrated.